BTC$62,163.00+2.25%
ETH$1,629.97+4.30%
USDT$0.9996+0.01%
BNB$594.21+3.46%
USDC$0.9997-0.01%
XRP$1.14+3.62%
SOL$65.14+5.09%
TRX$0.3274+1.69%
FIGR_HELOC$1.03+0.29%
DOGE$0.0848+4.39%
HYPE$58.51+0.68%
USDS$0.9998+0.01%
LEO$9.53-0.23%
RAIN$0.0133+3.12%
ZEC$418.58+17.35%
XLM$0.2066-2.27%
BTC$62,163.00+2.25%
ETH$1,629.97+4.30%
USDT$0.9996+0.01%
BNB$594.21+3.46%
USDC$0.9997-0.01%
XRP$1.14+3.62%
SOL$65.14+5.09%
TRX$0.3274+1.69%
FIGR_HELOC$1.03+0.29%
DOGE$0.0848+4.39%
HYPE$58.51+0.68%
USDS$0.9998+0.01%
LEO$9.53-0.23%
RAIN$0.0133+3.12%
ZEC$418.58+17.35%
XLM$0.2066-2.27%
Ocular Therapeutix stock jumped over 18% in premarket trading after rejecting Sanofi’s $16 per share buyout offer, as investors turned bullish on the company’s late-stage pipeline.